Long-term Risk of Malignant Neoplastic Disorders in Type 2 Diabetes Mellitus Patients with Metabolic Syndrome.

Oana AlbaiMirela Frandes Bogdan TimarDiana-Loreta PaunDeiana RomanRomulus Timar

Published in: Diabetes, metabolic syndrome and obesity : targets and therapy (2020)

The prevalence of malignant neoplastic disorders in our study group was 7.1%. Also, the prevalence of malignant neoplastic disorders was higher in patients with T2DM and MetS as compared to the general population of T2DM patients.

Keyphrases

metabolic syndrome
end stage renal disease
risk factors
ejection fraction
chronic kidney disease
newly diagnosed
prognostic factors
type diabetes
insulin resistance
cardiovascular disease
skeletal muscle
patient reported outcomes
adipose tissue
cardiovascular risk factors